• Clinical and Experimental Pediatrics
• /
• v.57 no.11
• /
• pp.465-471
• /
• 2014

Inflammatory bowel disease (IBD) is a chronic relapsing disorder of unknown etiology, which is believed to be multifactorial. Recently, the incidence of pediatric IBD has steeply increased in Korea since 2000. Poorly controlled disease activity can result in complications such as intestinal fistulae, abscess, and stricture, as well as growth retardation and delayed puberty in children. Because of a lack of confirmative tests, various diagnostic modalities must be used to diagnose IBD. Onset age, location, behavior, and activity are important in selecting treatments. Monogenic IBD must be excluded among infantile and refractory very-early-onset IBD. Early aggressive therapy using biologics has recently been proposed for peripubertal children to prevent growth failure and malnutrition.

• Proceedings of the Korean Vacuum Society Conference
• /
• 2013.02a
• /
• pp.196-196
• /
• 2013

가시광 영역에서의 높은 투과도와 낮은 전기 비저항을 갖는 ITO (Indium Tin Oxide) 박막은 현재 Display, Solar Cell, LED, Smart Phone 등 최첨단 IT산업에서 가장 많이 사용되고 있는 투명전극소재이다. IBD (Ion Beam Deposition)방법은 박막의 증착 방법 중 Plasma에서 독립적으로 이온만을 빔의 형태로 조사하여 박막을 증착하는 방법으로 기존 RF 또는 DC 스퍼터방법에 비해서 상대적으로 높은 진공도(low 10E-04 torr)와 비교적 높은 스퍼터 된 입자의 에너지를 가지는 등의 장점으로 증착 된 박막의 밀도, 거칠기가 향상되고 상대적으로 적은 결함을 가지는 박막의 제작에 사용되고 있는 기술이다. (주)인포비온에서는 IBD 기술과 더불어 표면만을 선택적으로 가열할 수 있는 EBA Technology를 사용하여 박막에 Energy를 전달하고, 이를 바탕으로 ITO 박막의 전기적, 광학적, 구조적인 특성의 변화를 관찰 연구했다 [1]. 본 연구에서는 기존의 Sputter 방법과 IBD 방법으로 증착 된 ITO 박막의 전기적, 광학적, 구조적인 특성 변화를 비교 관찰하였고, EBA 후처리로 ITO 박막을 상온에서 처리하여, 박막의 투과도, 면 저항, 미세구조의 변화를 관찰하였다. 각 특성의 변화는 UV-VIS, 4Point-Probe, TEM을 사용하여 분석하였고, 처리 전, 후의 박막의 결합에너지는 XPS로, 박막의 조성변화는 SIMS를 이용하여 각각 분석하였다.

• Hanyang Medical Reviews
• /
• v.33 no.1
• /
• pp.27-32
• /
• 2013

Inflammatory bowel diseases(IBD), including Crohn's disease and ulcerative colitis, are chronic inflammatory states of the intestinal tract. While the exact mechanisms inducing chronic inflammation are still unclear, it is hypothesized that the inflammation is caused in part by an inappropriate immune response to the intestinal microflora. Although inflammatory diseases are not directly linked to patient survival, symptoms of these diseases significantly decrease quality of life. The incidence rate is higher in western people than eastern people, but the incidence rate of IBD in eastern people, including Korean, is increasing. Recently, it has been reported that IL-17 is an important factor that appears to be involved in IBD induction and progression. This report reviews many recent papers reporting the relationship between IBD and IL-17, which may provide an understanding leading to new means of prevention and treatment for IBD.

• Clinical Endoscopy
• /
• v.55 no.6
• /
• pp.726-735
• /
• 2022

Inflammatory bowel disease (IBD) has a global presence with rapidly increasing incidence and prevalence. Patients with IBD including those with ulcerative colitis and Crohn's disease have a higher risk of developing colorectal cancer (CRC) compared to the general population. Risk factors for CRC in patients with IBD include long disease duration, extensive colitis, primary sclerosing cholangitis, family history of CRC, stricture, and prior dysplasia. Surveillance colonoscopy for CRC in patients with IBD should be tailored to individualized risk factors and requires careful monitoring every year to every five years. The current surveillance techniques are based on several guidelines. Chromoendoscopy with targeted biopsy is being recommended increasingly, and high-definition colonoscopy is gradually replacing standard-definition colonoscopy. However, it remains unclear whether chromoendoscopy, virtual chromoendoscopy, or white-light endoscopy has better efficiency when a high-definition scope is used. With the development of new endoscopic instruments and techniques, the paradigm of surveillance strategy has gradually changed. In this review, we discuss cutting-edge surveillance colonoscopy in patients with IBD including a review of literature.

• Bulletin of Food Technology
• /
• v.14 no.4
• /
• pp.87-94
• /
• 2001

Inflammatory bowel disease (IBD)환자의 유가공품 내성에 대한 병력과 의사나 영양학자로부터 받은 지침은 IBD환자들의 관리에 있어서 중요한 주안점이 된다. 대부분의 환자들이 불편 없이 매일 우유를 마실 수 있지만 부가적인 고찰에서는 개인적 요소와 크게 관련이 있는 특정요소가 있다는 것이다. 유가공품에 민감한 IBD 환자들의 진단으로 lactose의 내성과 흡수 장애, long- chain 지방산, 우유에 대한 알러지, 유가공품에 대한 심리적인 요소와 부정적인 인식 등이 있다. 유당 흡수장애의 발생빈도는 결장이나 ulcerative colitis (UC)를 포함하는 Crohndisease (CD)환자에서보다 소장의CD환자에서 더 높다. 유당 흡수장애의 후천적인 발생빈도는 유전적 요소에 기인하는 인종적 요인에 의해 주로 결정된다. 게다가 소장의 CD에서 유당 흡수장애는 lactase 효소보다도 세균성 이상증식이나 소장에서 통과하는 시간(small bowel transit time) 과 같은 요소에 의해 결정된다. 의사들이 IBD환자에게 내리는 지침에 있어서의 의견은 매우 다양하며, 진단이 내려지면 유가공품을 회피하라는 극단적인 충고가 있는 반면에IBD의 조절에 있어서 유가공품의 섭취를 줄이라는 제안을 내리는 경우도 있다. IBD환자들은 대중적인 식이요법 책의 저자들이나 의사들로부터 임의적인 제안과 환자들의 부정적 인식 때문에 우유 불내증이나 유당 흡수장애의 발병율의 근거가 거의 없는데도 필요이상으로 유가공품을 피한다. 따라서, 충분한 과학적.임상적 정보의 축적은 IBD환자들에게 유가공품의 섭취에 대한 지침을 설정하는 데에 유용하다.

• Korean Journal of Veterinary Service
• /
• v.21 no.3
• /
• pp.277-284
• /
• 1998

Serum samples were collected from 100 breeders and their progeny 600 broilers. The breeders and broilers were vaccinated against infectious bronchitis(IB), infectious bursal disease(IBD) and Newcastle disease(ND) viruses according to general vaccination program. The antibodies in serum samples against IB, IBD and ND viruses were detected by ELISA using commercial ELISA kit. Geometric mean titer(GMT) of ELISA was monitored from 1-day-old to 35-day-old broilers and compared to that of breeder chickens. The GMT of ELISA to IB, IBD and ND was declined half level of the day old broiler's antibody titers at about 4, 9 and 4 days of age. The GMT of ELISA to IB, IBD and ND was declined than that of protective antibody titer at about 12, 11, and 15 days of age. Thereafter, the GMT of ELISA to IB, ND were declined and disappeared according to age of broilers. The GMT of ELISA to IBD was declined according to age of broilers, but at 25 days of age increased and 31 days of age increased than that of protective antibody titer. Taken together, these studies led to conclusion that time-course of antibody titers of broilers from vaccinated breeders and that of progeny broliers which vaccinated according to vaccine program. Those are very important data to design vaccine program to breeders and broilers.

• Journal of Microbiology
• /
• v.41 no.2
• /
• pp.63-72
• /
• 2003

Chronic inflammatory bowel disease (IBD) such as Crohn's disease or ulcerative colitis, affects around 2 in every 1000 individuals in western countries and its incidence, particularly amongst children, is increasing. IBD shows extreme morbidity with impact on all aspects of quality of life. If left untreated, IBD can lead to death. Conventional treatment of IBD involves powerful immunosuppressive chemotherapies and surgical intervention. Long-term anti-inflammatory medication is required and so patients are often subject to a spectrum of unpleasant side effects. Interleukin-10 (IL-10) is a cytokine that acts to suppress inflammation. When however administered by injection, the high levels of IL-10 that are distributed throughout the body also lead to side effects. Lactococcus lactis can be genetically engineered to secrete biologically active cytokines. When applied to the mucosa, these L. lactis can actively deliver such cytokines. By use of this principle we developed a new therapeutic approach for IBD. Administration of L. lactis that secretes murine IL-10 cures and prevents IBD in mice. The use of the engineered L. lactis gets around the problem of delivering IL-10, allowing dramatic reduction of the effective dose. A sincere concern exists about the possible dangers of uncontrolled, deliberate release of genetically modified microorganisms, such as could occur following application in healthcare. We engaged in the establishment of adequate means for biological growth control of engineered L. lactis by targeted gene exchange between thyA and hIL-10.

• Journal of Neurogastroenterology and Motility
• /
• v.24 no.4
• /
• pp.614-627
• /
• 2018

Background/Aims Although functional abdominal pain disorders (FAPDs) are common in children, the accurate pathogenesis of FAPDs is not known yet. Micro-inflammation, particularly tissue eosinophilia of gastrointestinal (GI) tract, has been suggested as the pathophysiology observed in several GI disorders. We aimed to evaluate eosinophilic infiltration throughout the entire GI tract in children with FAPDs, compared to those with inflammatory bowel diseases (IBD) and to normal reference values. Methods We included 56 children with FAPDs, 52 children with Crohn's disease, and 23 children with ulcerative colitis. All subjects underwent esophagogastroduodenoscopic and colonoscopic examination with biopsies. Tissue eosinophil counts were assessed in 10 regions throughout the GI tract. Results Eosinophil counts of the gastric antrum, duodenum, terminal ileum, cecum, and ascending colon were significantly higher in children with FAPDs compared to normal reference values. Eosinophil counts of the stomach and the entire colon were observed to be significantly higher in children with IBD than in those with FAPDs. Even after selecting macroscopically uninvolved GI segments on endoscopy in children with IBD, eosinophil counts of the gastric body, cecum, descending colon, sigmoid colon, and the rectum were also significantly higher in children with IBD than those with FAPDs. Conclusions Significantly high eosinophil counts of the stomach and colon were observed in the order of IBD, followed by FAPDs, and normal controls, regardless of endoscopically detected macroscopic IBD lesions in children. This suggests some contribution of GI tract eosinophils in the intrinsic pathogenesis of FAPDs in children.

• Asian Pacific Journal of Cancer Prevention
• /
• v.16 no.5
• /
• pp.1945-1952
• /
• 2015

Inflammatory bowel disease (IBD) is a disease strongly associated with colorectal cancer (CRC) as a well-known precancerous condition. Alterations in DNA methylation and mutation in K-ras are believed to play an early etiopathogenic role in CRC and may also an initiating event through deregulation of molecular signaling. Epigenetic silencing of APC and SFRP2 in the WNT signaling pathway may also be involved in IBD-CRC. The role of aberrant DNA methylation in precancerous state of colorectal cancer (CRC) is under intensive investigation worldwide. The aim of this study was to investigate the status of promoter methylation of MGMT-B, APC1A and SFRP2 genes, in inflamed and normal colon tissues of patients with IBD compared with control normal tissues. A total of 52 IBD tissues as well as corresponding normal tissues and 30 samples from healthy participants were obtained. We determined promoter methylation status of MGMT-B, SFRP2 and APC1A genes by chemical treatment with sodium bisulfite and subsequent MSP. The most frequently methylated locus was MGMT-B (71%; 34 of 48), followed by SFRP2 (66.6 %; 32 of 48), and APC1A (43.7%; 21 of 48). Our study demonstrated for the first time that hypermethylation of the MGMT-B and the SFRP2 gene promoter regions might be involved in IBD development. Methylation of MGMT-B and SFRP2 in IBD patients may provide a method for early detection of IBD-associated neoplasia.

• Korean Journal of Clinical Pharmacy
• /
• v.29 no.2
• /
• pp.79-88
• /
• 2019

Backgrounds: Inflammatory bowel disease (IBD) including ulcerative colitis (UC) and Crohn's disease (CD) increased prevalence and economic burden. Objectives: This study aimed to investigate drug use pattern in IBD patients in a real world. Methods: National Health Insurance claim data from 2010 to 2014 were used in this population-based study. All IBD patients diagnosed during study period were enrolled. IBD medications included 5-aminosalicylic acid (ASA), glucocorticoid, immunomodulator and anti-tumor necrosis factor-${\alpha}$ agent(anti TNF-${\alpha}$). Growth rate of IBD prevalence, prescribed drug classes, duration of drug therapy and medication cost were analyzed. Number and percentage of patients for categorical variables, and mean and median for continuous variables were presented. Results: Total numbers of patients were 131,158 and 57,286 during 5 years, and their annual growth rate were 3.2 and 5.7% for UC and CD. UC and CD were prevalent in the 40-50 (41.2%) and 20-30 age groups (36.0%). About 60% of IBD patients was prescribed any of medications. 5-ASA was the most frequently prescribed, followed by corticosteroid and immunomodulator. Anti TNF-${\alpha}$ use was the lowest, but 5 times higher than UC in CD. Combination therapies with different class of drugs were in 29% for UC and 62% for CD. Mean prescription days per patient per year were 306 and 378, and the median medication cost per patient per year was KRW 420,000 (USD 383) and KRW 830,000 (USD755), for UC and CD, respectively. Conclusions: Increasing prevalence of IBD requires further studies to contribute to achieve better clinical outcomes of drug therapy.